TEVA - Teva Pharmaceutical Industries Limited
22.47 +0.01 (0.04%)
Pre-Market: 4:16AM EDT
| Previous Close | 22.12 |
| Open | 22.41 |
| Bid | 22.50 x 800 |
| Ask | 22.54 x 1100 |
| Day's Range | 21.70 - 22.56 |
| 52 Week Range | 10.85 - 25.14 |
| Volume | 9,119,695 |
| Avg. Volume | 10,340,515 |
| Market Cap | 22.881B |
| Beta | 1.11 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -15.79 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | 2017-11-27 |
| 1y Target Est | 21.09 |
Yahoo Finance Video•17 hours agoWarren Buffett ups his stake in Apple
Warren Buffett's Berkshire Hathaway raises its stake in Apple by nearly 5%. Yahoo Finance's Seana Smith, Andy Serwer, Myles Udland, and Dan Roberts discuss along with National Taxpayers Union Senior Fellow, Mattie Dupler.
- CNBC Videos•18 hours ago
Berkshire Hathaway adds to Apple, Teva stakes
CNBC's Leslie Picker reports the details of Berkshire Hathaway's 13F filing inlcuding increased stakes in Apple and decreasing some of its airline holdings.
- InvestorPlace•14 hours ago
Heat Biologics Stock Is a Worthwhile, Speculative Bet
Investors still waiting for Heat Biologics (NASDAQ:HTBX) to trade at a market cap of $100 million will have to wait longer. The biotechnology company, whose market capitalization is just $43 million, which puts it in the nano-cap territory, does not have much to offer except for hope. On May 3, HTBX stock slumped by around 50% when the company filed a preliminary prospectus for the public sale of nearly 4.3 million shares.
- Kiplinger•15 hours ago
11 Stocks Warren Buffett Is Buying or Selling
Warren Buffett, chairman and CEO of Berkshire Hathaway (BRK.B, $205.83), wasn't kidding when he said he couldn't get enough bites of Apple's (AAPL) stock. The Oracle of Omaha added to Berkshire Hathaway's already hefty stake in the iPhone maker during the three months ended June 30. Apple has since gone on to become the first U.S. company to top $1 trillion in market value. Buffett has made his ardor for Apple well-known, but the world's greatest value investor made a number of other noteworthy moves in the second quarter, according to a new 13F regulatory filing. (Large investors such as Berkshire are required to disclose their holdings to the Securities and Exchange Commission every three months.) The big picture remains the same. Buffett is, as always, bullish. In total, Berkshire spent $6.1 billion on stocks in the second quarter. And since it can be instructive to see what Buffett has been up to, we took a closer look at what Berkshire has been buying and selling. Keep in mind that bigger investments are thought to be made by Warren Buffett himself, while smaller positions are believed to be handled by lieutenants Ted Weschler and Todd Combs. With that caveat in mind, here are the most notable recent changes to Berkshire Hathaway's stock holdings. SEE ALSO: 20 Dividend Stocks to Fund 20 Years of Retirement
Market Realist•19 hours agoA Financial Overview of Bausch Health Companies in August
In the first half of 2018, Bausch Health reported revenue of $4.1 billion compared to $4.3 billion in the same period last year. Bausch Health reported net income of -$873 million in the second quarter compared to -$38 million in the same period last year. In the first half of 2018, Bausch Health reported net income of -$3.45 billion compared to -$590 million in the same period last year.
- TheStreet.com•19 hours ago
Buffett Ups Stake in Teva
Warren Buffett continues to bet on Teva Pharmaceutical Industries Ltd. disclosed in a Form 13-F filing with the Securities and Exchange Commission after the market close on Tuesday, Aug. 14, that it had increased its stake in Teva in the second quarter. Berkshire Hathaway raised its stake to 43.2 million shares, worth $1.05 billion as of June 30, up from 40.5 million shares worth $692.8 million as of March 31.
- Motley Fool•20 hours ago
3 Stocks for Warren Buffett Fans
If you like the Oracle's style, these stocks are for you.
Market Realist•20 hours agoHow Analysts View Bausch Health Companies in August
After the first half of 2018, Bausch raised its full-year adjusted EBITDA guidance from $3.15 billion–$3.30 billion to $3.20 billion–$3.35 billion. In August, Bausch Health’s wholly owned subsidiary Salix Pharmaceuticals and US WorldMeds announced the launch of Lucemyra 0.18 mg tablets in the US market. Right now, Lucemyra is the first and only non-opioid drug indicated for the mitigation of opioid withdrawal symptoms for facilitating rapid opioid discontinuation in adults.
- ACCESSWIRE•22 hours ago
Today's Research Reports on Trending Tickers: Teva Pharmaceutical and Canopy Growth
NEW YORK, NY / ACCESSWIRE / August 15, 2018 / U.S. equities snapped losses on Tuesday, as panic over Turkey’s currency eased and market participants focused on upbeat corporate earnings and strong economic ...
- Market Realist•23 hours ago
Analysts’ Recommendations for GlaxoSmithKline Stock
This year, analysts expect GlaxoSmithKline’s (GSK) revenue to grow 0.4% YoY (year-over-year) to ~30.3 billion British pounds from ~30.2 billion pounds, and its income margin to narrow YoY to 17.9% from 18.1%. They expect it to report EPS of 110.75 pence.
Associated Press•yesterdayWarren Buffett's firm adds to Apple, Teva investments
OMAHA, Neb. (AP) — Investor Warren Buffett's company added to its stakes in Apple and Israeli drugmaker Teva Pharmaceuticals in the second quarter while tweaking several of its other stock investments.
- Reuters•2 days ago
Berkshire boosts Goldman, Teva stakes; buys more Apple
Warren Buffett's Berkshire Hathaway Inc boosted its investments in Goldman Sachs Group Inc and Israel's Teva Pharmaceutical Industries Ltd during the second quarter and confirmed it has expanded its already ...
- CNBC•2 days ago
Stocks making the biggest moves after hours: EGN, TEVA & more
Energen EGN surged more than 7 percent in after-hours trading after Diamondback Energy FANG announced it was acquiring the oil and gas company for about $9.2 billion, including debt, or $84.95 per share. Diamondback's stock, meanwhile, lost 7.3 percent. Teva Pharmaceuticals TEVA rose 1.2 percent after a regulatory filing showed Warren Buffett's Berkshire Hathaway increased its position by 6.7 percent during the second quarter.
- Bloomberg•3 days ago
The Unlikely Source of a Healthtech Revolution
For decades, Israelis in the prescription drug industry pretty much faced a binary choice: work for Teva Pharmaceutical Industries Ltd. or emigrate. Instead, Teva’s downsizing has given new vigor to Israel’s life sciences industry. Veterans of the company have launched or joined startups that seek novel ways to discover drugs, develop software to help physicians work more efficiently, or tap technology that lets patients monitor their health.
